Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 8, 2008, Pages 1067-1073

  Giovanella, Luca ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Assay; Differentiated thyroid carcinoma; Functional sensitivity; Thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HETEROPHILE ANTIBODY; IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; THYROXINE;

ANALYTIC METHOD; ASSAY; CANCER RECURRENCE; CHEMOLUMINESCENCE; CLINICAL LABORATORY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; IMMUNOCHEMILUMINESCENT ASSAY; IMMUNOLUMINOMETRIC ASSAY; IMMUNORADIOMETRIC ASSAY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY CONTROL; SHORT SURVEY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID GLAND; THYROIDECTOMY;

BLOOD CHEMICAL ANALYSIS; FOLLOW-UP STUDIES; HUMANS; RECURRENCE; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 50249124644     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.212     Document Type: Short Survey

References (30)

1. Schlumberger M. Medical progress: papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
2. Klain M, Richard M, Leboulleux S, Baudin E, Schlumberger M. Radioiodine therapy for papillary and follicular thyroid carcinoma. Eur J Nucl Med 2002;29:S479-85.
3. Pacini F. Follow-up of differentiated thyroid cancer. Eur J Nucl Med 2002;29:492-6.
4. Cailleaux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? J Clin Endocrinol Metab 2000;85:175-8.
5. Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid carcinoma without diagnostic (131)I scanning. J Clin Endocrinol Metab 2000;87:1486-9.
6. Mazzaferri E, Robbins RJ, Spencer CA, Bravermann LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41.
7. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
8. Zanotti-Fregonara P, Khoury A, Duron F, Keller I, Bouchard P, Devaux JY, et al. Which thyroid cancer patients need periodic stimulation tests? Eur J Nucl Med Mol Imaging 2007;34:541-6.
9. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, et al. Limited value of repeat recombinant thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008;93:76-81.
10. Feldt-Rasmussen U, Petersen PH, Blaabjerg O, Horder M. Long-term variability in serum thyroglobulin and thyroid related hormones in healthy subjects. Acta Endocrinol (Copenh) 1980;95:328-34.
11. Demers CM, Spencer CA. Laboratory support for the diagnosis and monitoring of thyroid disease. National Academy of Clinical Biochemistry ed. Available at: http://www.nacb.org/lmpg/thyroid_lmpg_pub.stm. Accessed November 14, 2007.
12. Gardner DF, Rothman J, Utiger RD. Serum thyroglobulin in normal subjects and patients with hyperthyroidism due to Graves' disease: effects of T3, iodide, 131I and antithyroid drugs. Clin Endocrinol 1979;11:585-94.
13. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996;42:164-73.
14. Feldt-Rasmussen U, Profilis C, Colinet E, Black E, Bornet H, Bourdoux P, et al. Human thyroglobulin reference material (CRM 457). 1st Part: assessment of homogeneity, stability and immunoreactivity. Ann Biol Clin 1996;54:337-42.
15. Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Clin Endocrinol 2007;67:547-51.
16. Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain autoantibodies. Clin Chem 1997;43:413-5.
17. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-75.
18. Preissner CM, O'Kane DJ, Singh RJ, Morris JC, Grebe SK. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assay. J Clin Endocrinol Metab 2003;88:3069-74.
19. Giovanella L, Ghelfo A. Undetectable serum thyroglobulin due to negative interference of heterophile antibodies in relapsing thyroid carcinoma. Clin Chem 2007;53:1871-2.
20. Cole TG, Johnson D, Eveland BJ, Nahm MH. Cost-effective method for detection of "hook-effect" in tumor marker immunometric assays. Clin Chem 1993;39:695-6.
21. Souza do Rosario PW, Ribeiro Borges MA, Fagundes TA, Franco AC, Purisch S. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Clin Endocrinol 2005;62:121-5.
22. Persoon AC, Jager PL, Sluiter WJ, Plukker JT, Wolffenbuttel BH, Links TP. A sensitive Tg assay or rhTSH stimulated Tg: what's the best in the long-term follow-up of patients with differentiated thyroid carcinoma? PLoS ONE 2007;2:e816. Accessed November 17, 2007.
23. Giovanella L, Ceriani L. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clin Chem Lab Med 2002;40:480-4.
24. Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F, Spriano G. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med 2006;44:648-52.
25. Smallridge RC, Meek S, Morgan MA, Gates GS, Fox TP, Grabe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7.
26. Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, et al. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol 2007;67:434-41.
27. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007;92:2487-95.
28. Zophel K, Wünderlich G, Smith BR. Serum thyroglobulin measurements with high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003;13:861-5.
29. Heemstra KA, Lyu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol 2007;66:58-64.
30. 131I negative whole body scans, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated? Thyroid 1997;7:669-72.